HeyJaredJames Halley
- Indexed articles, last 90 days
- 47
- Latest publication
- Sep 20, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 5, 2026
Latest articles
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook (opens the original)
Read excerpt
Shares of Ionis Pharmaceuticals (NASDAQ: IONS) are down more than 40% so far this year and are almost half of their 52-week high of $86.74. While there are plenty of valid reasons for that tumble, analysts still average a lofty price target of $83.82 for the stock, with most putting it as a buy or a strong buy. The company focuses on neurology treatments and cardiometabolic diseases and has six approved therapies, mostly for rare diseases: Zanvastro treats Alexander disease, a brain disorder; Da
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder (opens the original)
Read excerpt
Bristol Myers Squibb (NYSE: BMY) is up a little more than 17% so far this year. Analysts don't seem that optimistic about the pharmaceutical stock, with an average price target of $66.71, just over $3 above its current trading price. The bear case for the stock is that several of its top sellers, including Eliquis and Opdivo, are facing patent expirations. However, that's discounting the rise in the company's growth portfolio. Here are three reasons why the bull case for the stock is getting lou
Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now (opens the original)
Read excerpt
Kenvue (NYSE: KVUE) is often overlooked when investors think about the best healthcare dividend stocks. The company was only spun off from Johnson & Johnson three years ago, but counting its time as the consumer healthcare division with the parent company, it has increased its dividend for 64 consecutive years. That makes it a Dividend King, one of the few companies that have increased their dividends for 50 or more consecutive years. It's not just longevity that makes Kenvue a good dividend sto
A $1.5 Trillion Defense Budget Is on the Table. Here's the 1 Defense Stock I'd Buy First. (opens the original)
Read excerpt
Geopolitical pressures, from the Iran war to U.S.-China conflicts and the Russia-Ukraine war, provide plenty of reasons for defense stocks to have tailwinds in 2026. That's because these pressures are likely to increase global defense spending. At home, the fiscal 2027 National Defense Authorization Act, passed by the House on July 22 but still awaiting a vote in the Senate, proposes a record $1.15 trillion in U.S. military spending. Plenty of defense stocks benefit from that extra spending, but
3 Reasons SpaceX Stock Could Crash in Q4 -- and 1 Reason It Won't (opens the original)
Read excerpt
Space Exploration Technologies (NASDAQ: SPCX) had a strong positive impact on space stocks when it debuted through an initial public offering (IPO) on June 12. SpaceX shares were priced at $135 per share for the IPO, but the stock opened that day to the public at $150. It reached an intraday high of $176.52 before closing at $160.95. Overall, though, the stock is down more than 7% this year, unless you were fortunate enough to buy it at its IPO price. Here are three reasons why the stock could c
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.